Webinars

​​Join BIO Business Solutions for a two-day webinar series highlighting the latest products, services, and solutions that member companies rely on every day as they prepare for growth.

Each session features concise, 10-minute presentations from trusted BIO Preferred Providers, who will share what's changing across the industry, emerging trends they're seeing, common operational challenges, and new service capabilities. You'll also learn about the exclusive savings and value-added benefits available through your BIO or state association membership.

Whether you're focused on optimizing lab operations, strengthening business functions, or planning for future growth, BIO Savings Week offers practical insights and actionable ideas from partners that support life science companies every day.

In this webinar, learn about HR, finance, software, compliance, and other business solutions that help organizations scale. Featuring: 

• ADP
• BiotechExec
• Corporate Traveler
• PSC Biotech Corporation
• PSC Software

Walk away with fresh ideas, new resources, and one key takeaway from every partner on what life science companies should be thinking about over the next 12 months.

Join BIO Business Solutions for a two-day webinar series highlighting the latest products, services, and solutions that member companies rely on every day as they prepare for growth. 

Each session features concise, 10-minute presentations from trusted BIO Preferred Providers, who will share what's changing across the industry, emerging trends they're seeing, common operational challenges, and new service capabilities. You'll also learn about the exclusive savings and value-added benefits available through your BIO or state association membership. 

Whether you're focused on optimizing lab operations, strengthening business functions, or planning for future growth, BIO Savings Week offers practical insights and actionable ideas from partners that support life science companies every day. 

In this webinar, we explore solutions for lab and equipment procurement, facilities, shipping, waste management, and office operations. 

Featuring:

• Airgas Healthcare
• American Laboratory Trading (ALT)
• SU Group
• UPS Healthcare
• VWR, part of Avantor  

Walk away with fresh ideas, new resources, and one key takeaway from every partner on what life science companies should be thinking about over the next 12 months. 

Join us for a discussion on the current life science investment landscape ahead of London Life Sciences Week and the Jefferies London Healthcare Conference. Hear perspectives from investors and capital markets leaders on where capital is flowing, what they're looking for in companies, and how management teams can prepare for productive business development and financing meetings. 

Gain the insights you need to navigate today's investment landscape, then put them into practice with BIO Partnering @ London Life Sciences Week. Register to connect with investors, biopharma leaders, and potential partners, and start building your meeting schedule. https://llsw.bio.org/ 

As monoclonal antibody (mAb) programs approach IND, delays often stem from fragmented development, tech transfer complexity, and limited process efficiency.

In this webinar, Thermo Fisher Scientific presents a reengineered Path to IND for biologics platform that combines advanced platform science with integrated U.S.-based manufacturing to accelerate timelines and reduce risk.

Join our Head of Technical and Scientific Affairs to explore:

• Expanded mAb manufacturing capacity: Future drug substance and product capacity in Plainville, MA to ease constraints and increase availability at sites like Groningen (NL) and Lengnau (CH).
• Advanced CHO-K1 platform with AI/ML: High-performing CHO-K1 cell line and process intensification achieving up to 11 g/L,* and enhanced by AI/ML-driven vector design and clone optimization to boost expression, stability, and speed.
• Accelerated path to IND: End-to-end biologics platform delivering IND-ready material in as little as 8 months with titer levels of up to 8 g/L.*
• Integrated process characterization and validation: Risk-based approach to PC, PV, and tech transfer to strengthen process robustness and help to accelerate PPQ readiness.
• Risk-mitigated development approach: Combines QbD, stage-gate governance, and qualified scale-down models to help to reduce variability and enable more predictable scale-up.
• Flexible scale model: Single-use bioreactor strategy (500–5,000 L) across a global network to streamline tech transfer from development through commercial manufacturing.

Discover how integrating advanced cell line engineering, high-efficiency processes, and a unified U.S. manufacturing strategy can help bring your mAb therapy to IND faster—with greater control and confidence.

The Advanced Research Projects Agency for Health (ARPA-H) advances bold, innovative research to solve the most challenging health problems. Their programs span from fundamental science to translational medicine, driving breakthrough discoveries that transform patient care and public health outcomes. ARPA-H makes pivotal investments in breakthrough technologies and broadly applicable platforms, capabilities, resources, and solutions with the potential to transform important areas of medicine and health that cannot readily be accomplished through traditional research or commercial activity. ARPA-H solutions aim to benefit everyone. 

View this webinar to learn more about the ARPA-H Small Business Program, its research and funding programs, and opportunities for engagement featuring ARPA-H’s Small Business Program Portfolio Manager, Sam Gussman-Toh. 

This webinar is appropriate for companies at all stages of development who are interested in partnering with ARPA-H to bring their ideas to life. Topics covered include: 

• Funding opportunities, including those for small businesses 
• ARPA-H’s Small Business Innovation Research (SBIR) awards and Small Business Technology Transfer (STTR) solicitation 
• Engagement opportunities for industry, academia, government, and early adopters

Elevate your research with Google Cloud AI solutions for Healthcare and Life Sciences, designed to help your organization supercharge scientific breakthroughs. Join our upcoming webinar to discover how AI is helping to transform the laboratory landscape by automating the most time-consuming parts of the research cycle. 

From rapid hypothesis generation and intelligent experimental design to complex multi-modal data analysis, Google Cloud solutions like Co-Scientist, Alpha Genome, and Alpha Evolve can act as a force multiplier for your team. Learn how to: 

• Accelerate Discovery: Shorten the path from inquiry to impact with automated literature synthesis and real-time reasoning. 
• Optimize Workflows: Streamline lab operations and simulate experimental outcomes before picking up a pipette. 
• Unlock Innovation: Uncover hidden patterns in your data that traditional methods often miss. 

Whether you’re in drug discovery, materials science, or academic research, this webinar will show you how to merge human expertise with AI precision to stay at the forefront of innovation. Don’t miss the chance to see the future of science in action.

As life sciences companies rethink global supply chains, reshoring has become a strategic priority. But where in the U.S. can companies scale efficiently, access skilled talent, and remain cost-competitive?

This panel explores why Puerto Rico stands out as a proven and future-ready destination for bioscience investment. Hear directly from industry leaders who have established or expanded operations on the island, and gain insights into manufacturing capabilities, incentives, and the broader innovation ecosystem.

If you’re evaluating U.S. expansion, this conversation will provide a clear perspective on why Puerto Rico isn’t just part of the equation; it’s a strategic advantage.

​BIO would like to walk through three new offerings to BIO members:

1. BRIDGE – Given the rapidly evolving scientific and regulatory ecosystem, it is critical to have a real-time understanding of any shifts in regulatory predictability, efficiency, or regulator expectations. To address this gap, BIO is introducing BRIDGE (BIO Regulatory Issue Data Gathering & Engagement) to move from anecdotal feedback to a more structured data-collection framework that captures member-reported data on regulatory issues impacting the timely review and approval of an innovative drug or biologic regulated by the FDA. Through BRIDGE, BIO will systematically aggregate member data, identify trend-level regulatory challenges, and engage FDA as needed to improve visibility into areas of recurring friction.
2. Investor Connect Plus – An exclusive investor access program in partnership with LaunchBio for BIO members. This program facilitates targeted one-to-one meetings with institutional and strategic investors actively deploying capital. These monthly efforts will connect Launch Bio’s national network of curated investors with member companies and create meaningful pitch opportunities.
3. Tracxn – Another new partnership, Tracxn offers complimentary access to a database of 250K+ active global investors. A valuable tool to help you identify, screen, and connect with the right partners for your fundraising goals.

BIO Savings Week connects life science companies with the lab and business solutions available through their BIO or state life science association membership. Across three days, you will hear directly from BIO Business Solutions' preferred providers about programs tailored to different roles—from founders and operations leaders to lab managers and admins.

Designed for lab managers and R&D leaders, this webinar explores the lab solutions and benefits that support research environments—from equipment and lab supply procurement to safety and compliance.

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

BIO Savings Week connects life science companies with the lab and business solutions available through their BIO or state life science association membership. Across three days, you will hear directly from BIO Business Solutions' preferred providers about programs tailored to different roles—from founders and operations leaders to lab managers and admins.

This webinar will cover an overview of the savings and benefits supporting core business operations, from travel and logistics to office purchasing and secure data management.

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

BIO Savings Week connects life science companies with the lab and business solutions available through their BIO or state life science association membership. Across three days, you will hear directly from BIO Business Solutions' preferred providers about programs tailored to different roles—from founders and operations leaders to lab managers and admins.

This webinar provides a focused look at the foundational tools early-stage life science companies need to launch and scale. Learn how membership benefits support HR, finance, compliance, and leadership decisions during the earliest stages.

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

Get the inside track on oncology investment and partnering trends following JPM Week. Our panelists will highlight the most important oncology updates coming out of San Francisco and share what to expect heading into BIO Partnering for Oncology (May 29–June 2, 2026, in Chicago), BIO’s newest B2B event focused on accelerating cancer-therapeutics innovation and deal-making.

In September 2025, the U.S. FDA launched a major enforcement campaign targeting direct-to-consumer (DTC) pharmaceutical advertising that misleads patients or downplays risks. Following a September 2025 presidential directive, the agency announced hundreds of enforcement actions—including over 100 cease-and-desist letters—signaling a zero-tolerance stance toward unbalanced or deceptive ads. While most of the letters focused on DTC content, FDA also sent letters for health care provider (HCP) promotion. The message: Government scrutiny and enforcement will significantly increase for biopharma as well as medical device promotion. This webinar includes regulatory compliance and drug advertising compliance experts who dissect the FDA’s mindset and ways to proactively mitigate concerns.

In this webinar, panelists:
– Drill down into FDA’s renewed enforcement areas
– Dissect the implications of increased enforcement on the industry
– Identify specific cases that are clear examples for company concern
– Isolate the key principles for avoiding violations and demonstrating good faith

Join Thermo Fisher Scientific for an exclusive webinar introducing a transformative approach to biologics development and clinical scale-up. Their "Path to IND for Biologics" method accelerates the journey from DNA to IND/IMPD submission and first-in-human clinical trials in as few as 9 months. Dr. Elena Gontarz, a leading expert in the biologics industry, will guide you through this innovative process, leveraging AI/ML, transposase technology, and integrated solutions during the session: "Path to IND for Biologics: From DNA to First-in-Human in 9 Months." Following the presentation, Dr. Gontarz will answer audience questions and discuss how these novel strategies can streamline the development of complex biologics, such as Fc-fusion proteins and bispecific antibodies, driving them swiftly from development to commercialization.

Get a sneak peek on this novel platform 

Terms and Conditions: Titer levels provided are estimates based on third party results and may vary depending on molecule type or other factors. Timeline from DNA to drug product and start of clinical trials for all path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized after third party cell line development dates are available and confirmed. 9-month timeline will incur additional risk.

Learn more about Dr. Elena Gontarz's expertise and background:

https://www.patheon.com/us/en/insights-resources/blog/navigating-the-complexities-of-process-performance-qualification.html

https://www.patheon.com/us/en/insights-resources/blog/choosing-a-cdmo-who-is-a-true-bioproduction-expert.html

View this webinar for an in-depth exploration of today's complex global market landscape. This panel will address the challenges of launching new therapies in multiple countries, focusing on early decision points for risk mitigation and maximizing supply chain resiliency. Discover how Cencora's global capabilities and flexible solutions can strengthen supply chain resilience amidst evolving challenges.
 

Moderator: Sandra Anderson, Senior Vice President Commercialization, Cencora

Panelists:

• Glenn Pauly, Chief Commercial Officer, Alzheon
• Graham Goodrich, Chief Commercial Officer, Apnimed
• Leigh Shultz, PhD, Associate Vice President & International Head of Trade Channel Strategy & Enablement, Merck & Co.
• Kevin McDermott, Vice President International Commercialization, Cencora
• Tom Doyle, Head of U.S. Commercial Solutions, Cencora

More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.

In this webinar, learn how companies are updating their approach to R&D, with a focus on:

1. AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
2. AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
3. Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs

With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.

BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below.  The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.

Moderator:
– Anne-Virginie Eggimann, Tessera

Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)

Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals